A robust assay for routine measurement of blood-spot 17a-hydroxyprogesterone (17-0HP) concentrations has been developed using a rnagnetisable, solid-phase antiserum and an 12~I-radioligand. The working range of this assay (13·5-500 nmol/L) is well suited for the initial diagnosis of congenital adrenal hyperplasia (CAH) and for monitoring replacement therapy in CAH patients. Data derived from multiple blood-spot samples. collected on two consecutive days. provide 17-0HP profiles. These profiles have been used to construct a chart allowing a rapid visual assessment of the efficacy of replacement therapy in CAH patients. Measurement of 17-0HP in the blood-spots of overtreated patients and accurate determination of normal range values in healthy infants relied on development of a sensitive assay (range 1·7-34 nmol/L). In the blood-spots of normal male (n=50) and female (n=50) infants collected 5-7 days after birth. l7-0HP concentrations were 7·62±2·55 nmol/L and 7·32±2·87 nmol/L respectively. Retrospective measurement of this steroid in samples from known CAH patients (n=4). which had values ranging from 224 to 2145 nmol/L, support a role for measurement of blood-spot l7-0HP in high-risk screening programmes.
A robust assay for routine measurement of blood-spot 17a-hydroxyprogesterone (17-0HP) concentrations has been developed using a rnagnetisable, solid-phase antiserum and an 12~I-radioligand. The working range of this assay (13·5-500 nmol/L) is well suited for the initial diagnosis of congenital adrenal hyperplasia (CAH) and for monitoring replacement therapy in CAH patients. Data derived from multiple blood-spot samples. collected on two consecutive days. provide 17-0HP profiles. These profiles have been used to construct a chart allowing a rapid visual assessment of the efficacy of replacement therapy in CAH patients. Measurement of 17-0HP in the blood-spots of overtreated patients and accurate determination of normal range values in healthy infants relied on development of a sensitive assay (range 1·7-34 nmol/L). In the blood-spots of normal male (n=50) and female (n=50) infants collected 5-7 days after birth. l7-0HP concentrations were 7·62±2·55 nmol/L and 7·32±2·87 nmol/L respectively. Retrospective measurement of this steroid in samples from known CAH patients (n=4). which had values ranging from 224 to 2145 nmol/L, support a role for measurement of blood-spot l7-0HP in high-risk screening programmes.
Measurement of 17a-hydroxyprogesterone (17-OHP) is now accepted as a reliable test for the diagnosis of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiencies.":' Once treatment is started. replacement therapy needs to be carefully monitored to ensure optimal growth and reproductive potential. 4 Single, random measurements of 17-0HP are unreliable as an index of therapeutic control, because data interpretation is complicated by factors such as a circadian rhythm in 17-0HP concentrations. episodic fluctuations in the secretion of this steroid and the need for precise timing of sample collection in relation to glucocorticoid dosage. I.~. 6 Serial measurements of 17-0HP in samples collected throughout the day are therefore required to give a reliable index of control.
Multiple saliva samples are easy to collect in children over 3 years of age and have been used 7 -9 in serial measurements of 17-0HP. In
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neonates and younger children. however. saliva sampling is technically more difficult. Attention has therefore been directed towards measurement of 17-0HP in capillary blood spotted onto filter-paper (blood-spots). Ill. II since these samples are more easily collected from younger patients using an Autolet device.
Processing the large sample numbers generated by such multiple procedures requires development of reliable. high-throughput immunoassays. The small volume of plasma in each blood-spot imposes the additional requirement for a highly sensitive assay technique. This paper therefore describes a radioimmunoassay for the measurement of 17-0HP in bloodspots, which uses an antiserum coupled to a magnetisable, solid-phase support. together with an 12~I-radioligand. which satisfies these criteria.
The value of blood-spot 17-0HP for monitoring control has been evaluated in a group of treated CAH patients over a 2-year period.
Matched blood-spot and saliva samples were collected at home, whereas plasma samples were obtained at clinic. These data, in conjunction with clinical assessment of the degree of control, L' were used to establish 17-0HP values associated with optimal treatment. A normal range for blood-spot l7-0HP concentrations in healthy newborn infants has also been established, and the suitability of this assay in screening programmes is discussed.
Methods

SUBJECTS
A group of children (n=30), with CAH, attending the Paediatric Endocrine Clinic at the University Hospital of Wales were included in this study. In these patients, the efficacy of steroid replacement therapy was assessed'{ according to accepted clinical criteria. These included monitoring of growth velocity, skeletal maturity, signs of puberty, regularity of menses (in post-pubertal girls), together with the stigmata of glucocorticosteroid overdosage. At each visit, between 9.00 and 11.00 a.m., children provided saliva and capillary blood samples before a venous sample was collected. Bloodspots were prepared by spotting capillary blood into the circles provided on Guthrie cards of the type routinely used for neonatal screening for phenylketonuria and congenital hypothyroidism.
On two consecutive weekend days before their visit, children collected serial-matched saliva and capillary blood-spot samples at 8.00 a.m .. midday, 6 p.rn. and bedtime. Early morning samples were collected just prior to medication. The times of daily divided doses of steroid were recorded, and all samples were posted to the laboratory for analysis. Some older children, who were admitted to hospital for minor non-endocrine investigations, provided matched samples of plasma, capillary blood and saliva at 1-2 h intervals for 12 or 24 h. Plasma and saliva samples were stored at -20°C until assayed. Guthrie cards were stored in the dark over silica gel at room temperature and assayed within 2 weeks of receipt. Additional blood-spots were obtained from the Welsh Regional Screening Laboratories and were used to determine a normal range for blood-spot 17-0HP in newborn infants. 
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were measured using the specific radioimmunoassay of Dyas et al., 1J which features an 125 1_ radioligand and a magnetisable, solid-phase antiserum.
Blood-spot J7-0HP assay
Measurement of 17-0HP in blood-spots from treated CAH patients incorporated an alternative extraction procedure to that used in the routine assay. A disc (W' diameter) was punched out of each blood-spot on a Guthrie card and placed in a glass tube (I00X 12 mm) containing absolute alcohol (200 I-lL). After vortex-mixing, phosphate-buffered saline was added to each tube (300 I-lL, pH 7-4), the tubes were vortex-mixed again and allowed to stand at room temperature for 1 h. The eluted 17-0HP was then extracted into a diethyl ether/petroleum ether mixture (40/60 v/v; 2 mL) by placing the tubes on a multi-vortex mixer for 10 min. The buffer-ethanol mixture containing the disc was frozen (acetone/solid CO 2), the solvent decanted into polypropylene tubes (75x12 mm), dried under N 2 and then processed by the routine procedure.
Sensitive blood-spot assay
Measurement of the low concentrations of 17-OHP in blood-spots from normal infants and over-treated CAH patients required a more sensitive procedure. Greater sensitivity in the blood-spot assay was achieved by halving the volume of 1251_label (500 I-lL, 40 000 cpm on the day of preparation), increasing the dilution of the solid-phase antiserum (100 I-lL; 1/32000 dilution), and by incubating the tubes for 1 h at room temperature on an orbital shaker.
Results
ANALYTICAL VARIABLES
Dose-response curves
Standards prepared in ethanol had upper limits of 750 pg/lO I-lL in the routine assay and 50 pg/l0 I-lL in the sensitive assay; these concentrations corresponded to 500 and 34 nmol/L 17-0HP respectively. Problems caused by solvent and/or filter-paper residues were resolved by adding the ethanolic standards to tubes containing ether/petroleum ether (2 mL) which had previously been used to extract discs of blood-free filter paper. The dose-response curves and the corresponding precision profiles (Fig. 1) indicate the range of the sensitive (2·5 pg-50 pg; 1·7-34 nmol/L) and the routine (20 pg-750 pg; 13·5-500 nmol/L) blood-spot assay procedures.
Blood-spots
The amount of whole blood contained in a IN' disc was initially assessed by adding 125 1_ labelled 17-0HP to whole blood, applying the blood to Guthrie cards and punching out a series of discs. Counting the radioactivity associated with the discs and known volumes of blood showed that each disc contained 9±0·23 I-lL of blood.
Matched samples (n=45) of whole blood (10 I-lL) and plasma (5 I-lL), collected from patients attending the CAH clinic, were applied to filter paper. The data obtained from measurement of 17-0HP in these samples gave a regression (17P p1)=1·03 (17P hl)-+{)·82. The excellent correlation (r=0'991) permitted accurate interpolation of blood values to plasma values, allowing blood-spot 17-0HP concentrations to be reported as nmol/L in plasma.
In routine practice, processing of inadequate samples was avoided by excluding all bloodspots with a diameter of less than 8 mm. Similarly, discs were not punched from the edge of large spots, to avoid possible 'chromatographic effects'.
Recovery
Blood, obtained from healthy volunteers following administration of dexamethasone (2 mg; 0·5 mg 6-hourly), was pooled and shown to have no detectable concentrations of 17-OHP «1·7 nmol/L). Pooled blood was spiked with a high concentration of J7-0HP (4S0 nmol/L) and serially diluted in the same blood. Blood-spots were then prepared from each dilution, and assayed to give the concentrations and percentage recoveries shown in Table I .
Analysis of these serially diluted samples gave the regression equation y=0·99x+5·l nmol/L; r=0·999, indicating that recovery was greater than 9YYo and was linear over concentrations ranging from 3 to 450 nmol/L.
Precision
Blood from a healthy volunteer was spiked with 17-0HP at a range of concentrations relating to high, medium and low values in either the 'routine' or 'sensitive' dose-response curves. Blood-spots prepared from these pools were stored at room temperature over a desiccant and used as quality-control samples. The intraassay precision of both assays was assessed by replicate analyses of samples from the appropriate pool. Inclusion of quality-control samples, 
Stability of blood-spots
Replicate blood-spots were prepared with blood obtained from CAH patients with a wide taken from a subsequent pool, in consecutive assays allowed determination of inter-assay variation. The precision of both assays ( (Fig. 2a) indicated a slope of ()·98 and a negligible intercept (0,89 nmol/L) , assuming all blood-spots contained 4·5 ul, plasma. Similar analysis of the blood-spots/saliva data ( Fig. 2b) showed that the slope was 39 and the intercept ()·74 nmol/L.
Supporting evidence for the good correlation in 17-0HP concentrations in these three fluids was obtained by processing the matched, serial samples provided by some (n=6) of the older CAH patients. Representative data from one of these patients (Fig. 3) show that changes in 17-OHP secretion occurring at hourly intervals over a 24-h time span could be judged equally well by the changing concentrations of this steroid in blood-spots, plasma and saliva.
(b) 17-0HP profiles. Over the last 5 years, salivary 17-0HP profiles (which rely on four, timed samples collected at home on two consecutive days) have been used to monitor steroid replacement therapy in patients with range of endogenous 17-0HP concentrations. These were assayed periodically, and shown to be stable for at least 4 months under the stated conditions. CAH. As these patients have, for the past 2 years, also provided matched blood-spot samples. it has proved possible to establish the range of capillary blood 17-011P concentrations throughout the day associated with optimal treatment. These 'adequate-control' charts ( Fig. 4 ) allow rapid visual assessment of bloodspot and salivary 17-0HP profiles of individual patients. Those of patient JC, illustrated in Fig.  4 , show a strictly comparable pattern in 17-OHP concentrations in blood-spots (a) and saliva (b) throughout the day. Replacement therapy, judged either by blood-spot or salivary 17-0HP concentrations, is clearly sub-optimal, particularly in the latter part of the day.
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'High-risk' screening
In assessing the value of the 'sensitive assay' for use in a 'high-risk' screening programme, concentrations of 17-0HP in blood-spots from normal infants aged 5-7 days were determined. In a group of newborn boys (n=50) and girls (n=50) values were 7·02±2·55 nmol/L (range 3'0-17'0 nmol/L) and 7·32±2·H7 nmol/L (range 3·3-10-4 nmol/L) respectively. Those seen in low-birthweight infants (n=I00) were higher 13·2±1l·3 (range 4·2--65·6 nmollL). Values exceeded the upper limit of normality (17'0 nmol/L) in approximately 30% of babies included in a group with birthweights ranging from 1·0-2·0 kg; this value was exceeded in only 10% of babies in the 2·0-2·5 kg group. This finding accords with reports of increased plasma 17-0HP values in pre-term infants.l" Retrospective measurement of 17-0HP in Guthrie card blood-spots of six CAH patients, which had been stored for periods ranging from 2 to 4 years, showed that in four patients with 21-hydroxylase defects, values ranged from 224 to 2145 nmollL, whereas in two patients with ll~-hydroxylase defects, values were lower (13·5 and 59 nmol/L). As blood-spot 17-0HP may not be stable for such long time-periods, samples collected from normal infants (n=50) which had been stored for a similar period of time were also assayed; 17-0HP values in these samples ranged from 3·9 to 20·2 nmollL (mean 0·H±3·3 nmol/L). These data indicate that blood-spot 17-0HP values will clearly identify the 21-hydroxylase defect but, as expected, the test is not suitable for the diagnosis of 1l~ hydroxylase defects. Several immunoassay procedures have been described for the measurement of 17-0HP in capillary blood absorbed onto filterpaper.!': 15-lK 'Direct' assays not requiring solvent extraction'": 19 provide the highthroughput necessary for large-scale screening programmes, but generally lack both sensitivity and specificity. They are, therefore, unsuitable for accurate monitoring of glucocorticoid replacement therapy in CAH patients and for establishing 'normal range' values in healthy children. Most procedures use solvent extraction to separate 17-0HP from blood. In our experience, and that of others.j" extraction without prior wetting of the paper with buffer leads to low, inconsistent recovery. If steroids are to be leached from the paper, and then extracted, with high overall efficiency, details of the techniques are critical, but have been inadequately described in earlier publications.
Some recommend removal of the discwhich is time-consuming and leads to variable losses due to occluded fluid. Others leave the disc in situ but, in our experience, disintegration of the disc during vortex-mixing resulted in the formation of stable emulsions and elution of pigmented contaminants, which caused high blank 17-0HP values. These problems were resolved by prior addition of ethanol to the disc. This effectively fixed contaminants to the filter-paper and firmed the disc so that it remained intact on vortex-mixing. Addition of ethanol also facilitated elution of 17-0HP into buffer and subsequent solvent extraction of this mixture effected almost quantitative recovery of 17-0HP from the blood-spots. This extraction step, although limiting throughput, improved the specificity of both the routine and sensitive procedures. This, in turn, was reflected in blood-spot 17-0HP values lower than those generally reported. 11. 18, 19 Eliminating problems of 'assay blanks' allowed development of the 'sensitive' assay. Although assays with high detection limits are acceptable in the diagnosis of CAH, where infants commonly have values exceeding 200 nmol/L, they are of limited value in monitoring treatment. By contrast, the sensitive assay reported here provides useful information in over-treated patients and is better suited for establishing reference ranges in unaffected infants. Long-term quality control of assays used for monitoring is obviously essential. We have therefore chosen to use ethanolic standards rather than blood-spot standards, for if standards and quality control samples are prepared and stored identically, checks on stability are precluded.
The good correlation in blood-spot and salivary 17-0HP concentrations indicates that 'at home' collection of the samples required for monitoring replacement therapy, which in the past was restricted to salivary sampling, may now be extended to include blood-spots. Parents of infants and younger children find little difficulty in collecting the 8-10 capillary blood samples needed for constructing the 2-day 17-0HP profiles. Opinion was divided among the older children; some preferred to collect capillary blood, others saliva.
The correlation between 17-0HP in plasma and blood-spots of CAH patients was also good (r=0·994), suggesting that the assumption that the disc contained 4·5 ul, of plasma (used in the calculation of blood-spot values) was valid. A similar approach was used by Sol yom and co-workers/" and has the advantage that bloodspot values then closely accord with plasma values, thus minimising problems of data interpretation for clinicians.
The question of whether national screening for CAH should be introduced remains debatable. For such screening, high-throughput assays are essential even at the cost of specificity and sensitivity. The assays reported here do not have the required throughput. We favour measurement only in those infants showing signs/symptoms suggestive of CAH,4 and for this purpose the routine assay is well suited. Blood-spots from all four infants with 21-hydroxylase defects had l7-0HP concentrations (224--2145 nmollL) which were clearly distinguishable from the highest value (65,6 nrnol/L) observed in low birth-weight infants.
Blood-spots are stable at ambient temperatures and unlike plasma and saliva may be easily transported by mail without fear of sample spillage. This sampling procedure would therefore appear ideal in the initial diagnosis of a condition like CAH where patients are first seen at district hospitals and samples are then sent to central laboratories for assay. Whilst plasma remains in common usage for diagnosis, non-invasive procedures employing blood-spots and saliva have become accepted for monitoring replacement therapy in CAH. The introduction of sensitive, specific assays for blood-spot 17-0HP, coupled with the day-return of results and easy, visual data interpretation, has facilitated introduction of this alternative multiplesampling procedure and has ensured recognition of over-treatment before signs of hypercortisolism arise.
